Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- WDFC -4%
- PSMT -3.9%, (PriceSmart misses by $0.15, reports revs in-line; June same store sales -1.9% vs -3.0% Retail Metrics consensus)
- HELE -2.6%
Select drug related names showing weakness (may be related to JUNO news): KITE -7.6%, BLUE -4.8%, CELG -1.4%,SHPG -1.3%, NVS -1.1%, AZN -1%, SNY -0.7%, GSK -0.5%
Other news:
Other news:
- JUNO -26.1% (Juno Therapeutics receives notice from the FDA that a clinical hold has been placed on the Phase II clinical trial of JCAR015 )
- TTOO -6% (pushing out the expected timeline for the completion of T2Candida cartridge trial; separately co appoints Joanne Spadoro, Ph.D., as COO)
- KCG -2.4% (files for offering of 20.21 mln shares of Class A common stock, 2.70 mln Class A Warrants, 2.70 mln Class B Warrants, 2.70 mln Class C Warants, and an additional 8.01 mln shares of Class A common stock on behalf of selling shareholders )
- LEDS -2.1% (following 200%+ move Thursday)
- GALE -2% ( prices a 28 mln share registered direct offering at $0.45/share with warrants to purchase up to 14 mln shares at $0.65/share )
Analyst comments:
- AMD -4.6% (downgraded to Underperform at Bernstein)
- DEO -1.2% (downgraded to Equal Weight from Overweight at Barclays)
- AV 1.3% (downgraded to Equal Weight from Overweight at Barclays)